Pomerantz LLP is investigating Alibaba Group for potential securities fraud and unlawful business practices following reports that Alibaba illicitly accessed AI technology and failed to prevent illegal pharmaceutical sales on its platform. Alibaba's stock dropped after these revelations and a $600 million settlement with the U.S. Department of Justice over the pharmaceutical violations. The investigation could lead to a class action lawsuit representing affected investors.
The Rosen Law Firm has launched a class action lawsuit against Alibaba Group Holding Limited following allegations that Alibaba misled investors by providing false business information. The claims stem from a Financial Times report accusing Alibaba o...
Seagate Technology and Nebius Group saw their common stock and convertible bonds increase during the quarter following strong earnings reports and robust revenue growth. In contrast, Eni's stock declined amid a broader energy sector selloff, despite ...
Alibaba's Cloud Intelligence Group has achieved a 46.1% average annual growth rate over the past decade, outpacing the overall company growth. This growth is supported by increased AI adoption and improved profit margins. Despite a decline in global ...
Anthropic CEO Dario Amodei clarified that his company does not support banning open-weight AI models, which users can download and modify. This statement follows a coalition of tech firms urging policymakers to avoid premature restrictions on such mo...
